Table 2.

Median (interquartiles), Wilcoxon rank-sum test p-value, median difference (atorvastatin – placebo), and 95% bootstrap confidence intervals for median difference. The concentration units are pM for serum and pM in homogenate (100 mg tissue/1 mL saline) for prostatic tissue steroid hormone profile. Cortisol and 11KA4 levels have decreased after atorvastatin intervention in the atorvastatin arm (n = 56) compared to placebo (n = 52), and the difference is statistically significant. After adjusting the Wilcoxon rank-sum test p-values for multiple comparison, the adjusted p-value for the 11KA4 difference between the study arms is 0.001. For prostatic tissue hormone profile, the 11KDHT, Estrone, and DHEA are significantly differing between the study arms (atorvastatin n = 51, placebo n = 48). After adjusting the p-values for multiple comparison all p-values inflate above significance level 0.05. In the serum, the median difference of 11KA4 is significantly differing between the study arms (−342.5, 95% bootstrap CI-505.23 −188.98). In the prostatic tissue, the median difference of 11KDHT is significantly differing between the study arms (−6.53, 95% bootstrap CI −12.80 −0.29).

Serum hormone	Placebo, median (Q1 – Q3), n = 52		Atorvastatin, median (Q1 – Q3), n = 56	p-value	Median diff.		95% bootstrap CI for median difference.
Cortisol		333,333.5 (267,289.25–420,965.5)	291,364.5 (234,340–358,946.75)	0.035		−41,969	−86,983.9	8754.69
Cortisone		61,173 (53,556–67,695)	57,485 (50,435.75–68,475.25)	0.202		−3688	−9014.5	1254.43
11KA4		960 (715.75–1254.25)	617.5 (506.5–825)	<0.0001		−342.5	−505.23	−188.98
11KT		1275.5 (826.25–1852.25)	1214.5 (829–1546.5)	0.324		−61	−456.66	264.04
11OHT		567 (444.75–800)	573.5 (444–728.25)	0.515		6.5	−173	133.64
11bOH A4		6043 (4073–8225.75)	5292.5 (4098–6489.5)	0.187		−750.5	−2033	360.08
Estrone		142.5 (109–189.5)	129 (104–160)	0.108		−13.6	−44.03	15.01
11DOX		849 (547.5–1372)	903 (563.25–1185.75)	0.963			−221.33	260.03
17OH Pregne		2815 (1928.25–4232.75)	2121.5 (1567–3472.25)	0.053		−693.5	−1656.03	168.71
DHEA		9862.5 (6098.75–11,945.25)	7479 (5098.25–10,040.75)	0.079		−2383	−4388	326
Androstenedione		2794.5 (1971.5–3702.5)	2598.5 (1949.25–3487)	0.322		−196	−620.09	219.01
Testo		15,058.5 (12,481.75–20,652.25)	15,613 (11,116.5–20,581.25)	0.742		554.5	−2877.69	2981
DHT		1252.5 (923–1648.25)	1248.5 (815.25–1720.5)	0.717		−4	−344.01	363
Androstanedione		212.5 (134.5–259)	166 (114.75–231.75)	0.066		−46.5	−83.013	20.5
17OH Proge		2430 (1579–3889.25)	2076.5 (1627–2738)	0.19		−353.5	−982.13	358
Pregnenolone		2232.5 (1514.75–2852.75)	1746 (1240–2689.75)	0.062		−486.5	−863.08	38.2
Progesterone		168 (127.25–287.25)	163.5 (112.75–204)	0.116		−4.5	−47.5	28
Prostatic tissue hormone	Placebo, median (Q1 – Q3), n = 48		Atorvastatin, median (Q1 – Q3), n = 51	p-value	Median diff.		95% bootstrap CI for median difference
Cortisol	1218.775 (603.0525–2476.285)		1605 (791.42–2561.97)	0.204	386.23		−182.19	868.96
Cortisone	225 (118.1375–437.7025)		280.25 (168.3–493.73)	0.196	55.25		−38.11	191.60
11KDHT	25.015 (19.1–34.3125)		18.49 (13.1–26.82)	0.027	−6.53		−12.80	−0.29
Estrone	10.62 (5.7525–13.7075)		12.08 (9.17–18.69)	0.044	1.46		−0.88	5.43
17OH Pregne	66.065 (49.155–106.5875)		68.77 (47.56–112.175)	0.703	2.71		−14.54	27.12
DHEA	2243.835 (1151.7075–3240.335)		3123.46 (1772.325–5043.845)	0.037	879.63		−20.65	1622.79
Androstenedione	11.325 (7.22–16.565)		11.08 (7.635–15.275)	0.966	−0.245		−3.28	3.06
Testo	10.08 (8.075–19.6925)		13.37 (7.72–31.145)	0.171	3.29		−0.29	8.24
DHT	824.325 (677.6175–1050.8925)		864.02 (684.585–1047.76)	0.958	39.70		−137.01	151.21
AndrostAnedione	77.55 (59.02–106.965)		78 (58.585–113.94)	0.853	0.45		−21.57	17.12
Pregnenolone	394.76 (268.285–548.795)		444.5 (273.615–699.67)	0.350	49.74		−50.00	160.87